16 completed, 11 active not recruiting, 4 recruiting, 3 not yet recruiting. 17 Phase 1, 12 Phase 2, 3 Phase 3, 3 Phase 4, 1 Early Phase 1.
Follow selpercatinib: new trials by email Literature Review of selpercatinib trials Research Report on selpercatinib
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of Selpercatinib (LY3527723) in Participants With Rearranged During Transfection (RET)-Altered Cancers in India Selpercatinib - Thyroid Neoplasms, Carcinoma, Non-Small-Cell Lung | Phase 4 | Not yet recruiting | Eli Lilly and Company | 30 | 2026-10-01 | 2026-10-08 |
| Feasibility Study for Repurposing RET Inhibitors Selpercatinib, Strength Assessment - Cachexia-Anorexia Syndrome | Early Phase 1 | Not yet recruiting | University of Oklahoma | 7 | 2026-02-26 | 2026-01-15 |
| Response to Neoadjuvant Treatment in Locally Advanced Thyroid Cancer Multitarget Tyrosine Kinase Inhibitors, BRAF inhibitor dabrafenib and MEK inhibitor trametinib, RET Inhibitor - Thyroid Cancer, Thyroid Neoplasms | Recruiting | Fujian Medical University | 120 | 2025-12-23 | 2026-02-19 | |
| Genotype-Driven Neoadjuvant Therapy for Locally Advanced Thyroid Cancer: A Real-World Cohort Study Dabrafenib, Trametinib, Selpercatinib - Thyroid Neoplasms | Phase 4 | Not yet recruiting | Fujian Medical University | 335 | 2025-07-01 | 2025-06-08 |
| ERectile Dysfunctions, gOnadotoxicity and Sexual Health Assessment in Men With Lung Cancer Alectinib, Brigatinib, Lorlatinib 100 mg - NSCLC Stage IV, Sex Disorder | Unknown | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | 80 | 2024-08-05 | 2024-08-09 | |
| Selpercatinib and Body Composition observation in patient under treatment, Selpercatinib - Thyroid Cancer | Completed | University of Pisa | 15 | 2024-04-12 | 2026-04-22 | |
| A Drug Drug Interaction (DDI) Study of Selpercatinib (LY3527723) and Rosuvastatin in Healthy Participants Rosuvastatin, Selpercatinib - Healthy | Phase 1 | Completed | Eli Lilly and Company | 28 | 2023-07-27 | 2025-09-16 |
| Restor. I-131 Upt. + Selpercatinib in RET F-P RAI-R TC Selpercatinib, Sodium Iodine I-131, rhTSH - Thyroid Cancer, Thyroid Carcinoma | Phase 2 | Recruiting | Massachusetts General Hospital | 30 | 2023-03-01 | 2024-12-12 |
| Testing the Use of Targeted Treatment for RET Positive Advanced Non-small Cell Lung Cancer Carboplatin, Pemetrexed, Selpercatinib - Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma | Phase 2 | Withdrawn | SWOG Cancer Research Network | 2022-07-25 | 2024-07-09 | |
| A Study of the Effect of Food on Selpercatinib (LY3527723) in Healthy Participants Selpercatinib - Healthy | Phase 1 | Completed | Loxo Oncology, Inc. | 46 | 2022-04-19 | 2025-03-21 |
| A Study of Selpercatinib After Surgery or Radiation in Participants With Non-Small Cell Lung Cancer (NSCLC) Selpercatinib, Placebo - Carcinoma, Non-Small-Cell Lung | Phase 3 | Active not recruiting | Eli Lilly and Company | 152 | 2021-12-20 | 2026-03-04 |
| A Relative Bioavailability Study of Selpercatinib (LY3527723) in Healthy Participants Selpercatinib - Healthy | Phase 1 | Completed | Loxo Oncology, Inc. | 42 | 2021-12-03 | 2025-03-17 |
| A Study Comparing Two Formulations of Selpercatinib (LY3527723) in Healthy Participants Selpercatinib - Healthy | Phase 1 | Completed | Loxo Oncology, Inc. | 224 | 2021-10-29 | 2025-03-17 |
| Selpercatinib for the Treatment of Advanced Solid Tumors, Lymphomas, or Histiocytic Disorders With Activating RET Gene Alterations, a Pediatric MATCH Treatment Trial Computed Tomography, Magnetic Resonance Imaging, Positron Emission Tomography - Hematopoietic and Lymphatic System Neoplasm, Recurrent Ependymoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 1 | 2021-05-03 | 2026-10-09 |
| A Drug Drug Interaction (DDI) Study of Selpercatinib and Dabigatran in Healthy Participants Dabigatran, Selpercatinib - Healthy | Phase 1 | Completed | Loxo Oncology, Inc. | 36 | 2021-03-05 | 2024-05-24 |
| Selpercatinib Before Surgery for the Treatment of RET-Altered Thyroid Cancer Quality-of-Life Assessment, Questionnaire Administration, Selpercatinib - Malignant Thyroid Gland Neoplasm, Poorly Differentiated Thyroid Gland Carcinoma | Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 30 | 2021-02-26 | 2026-05-20 |
| The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and Immunotherapy Erlotinib, Trastuzumab, Trastuzumab emtansine - Breast Cancer, Gastrointestinal Cancer | Phase 2 | Unknown | Fondazione per la Medicina Personalizzata | 400 | 2020-10-07 | 2023-10-03 |
| Targeted Treatment for RET Fusion-Positive Advanced Non-Small Cell Lung Cancer (A LUNG-MAP Treatment Trial) Selpercatinib - Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8 | Phase 2 | Active not recruiting | SWOG Cancer Research Network | 124 | 2020-04-08 | 2026-03-23 |
| A Study of Selpercatinib (LY3527723) in Participants With Advanced Solid Tumors Including RET Fusion-positive Solid Tumors, Medullary Thyroid Cancer and Other Tumors With RET Activation Selpercatinib - Solid Tumor, Medullary Thyroid Cancer | Phase 2 | Active not recruiting | Eli Lilly and Company | 77 | 2020-03-16 | 2026-08-07 |
| A Study of Selpercatinib (LY3527723) in Participants With Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer Selpercatinib, Carboplatin, Cisplatin - Non-Small Cell Lung Cancer | Phase 3 | Active not recruiting | Eli Lilly and Company | 261 | 2020-02-17 | 2026-10-21 |
Showing 20 of 38. Sign in to see all of them.
Carcinoma, Non-Small-Cell Lung (12) · Thyroid Neoplasms (9) · Carcinoma, Medullary (6) · Thyroid Cancer, Papillary (5) · Breast Neoplasms (4) · Lung Neoplasms (4) · Central Nervous System Neoplasms (3) · Colonic Neoplasms (3) · Neoplasms (3) · Sarcoma (3) · Thyroid Diseases (3) · Bronchial Neoplasms (2) · Carcinoma, Bronchogenic (2) · Endocrine Gland Neoplasms (2) · Endocrine System Diseases (2)
Eli Lilly and Company (18) · Loxo Oncology, Inc. (5) · Fujian Medical University (2) · National Cancer Institute (NCI) (2) · SWOG Cancer Research Network (2) · AstraZeneca (1) · Fondazione Policlinico Universitario Agostino Gemelli IRCCS (1) · Fondazione per la Medicina Personalizzata (1) · Fudan University (1) · M.D. Anderson Cancer Center (1) · Massachusetts General Hospital (1) · The Netherlands Cancer Institute (1) · University of Oklahoma (1) · University of Pisa (1)
United States (27) · Italy (10) · Australia (8) · China (7) · Japan (7) · Spain (7) · Canada (6) · France (6) · Germany (6) · South Korea (6) · Israel (5) · Netherlands (5) · Singapore (5) · United Kingdom (5) · Denmark (4)
Yasir Y Elamin (2) · Andrea Botticelli (1) · Andrea T Franson (1) · Donald W Parsons (1) · Dongmei Ji, M.D (1) · E.E. Voest, prof. (1) · Helena A Yu, MD (1) · Lori J. Wirth, MD (1) · Mark Zafereo (1) · Nirmal Choradia, MD (1) · Paolo Marchetti (1)
PMID 36657661, PMID 32027845, PMID 32846060, PMID 32846061, PMID 33150799, PMID 33591402, PMID 34088726, PMID 34292174, PMID 34389237, PMID 35086719, PMID 35353553, PMID 35378489, PMID 35598186, PMID 35923928, PMID 35930972, PMID 35950566, PMID 35969032, PMID 36062046, PMID 36108661, PMID 36122315, PMID 36870947, PMID 36996322, PMID 37265412, PMID 37315261, PMID 37424386, PMID 37655205, PMID 37870969, PMID 37870973, PMID 37934000, PMID 38630551, PMID 38661071, PMID 38828957, PMID 39085487, PMID 39094065, PMID 39471424, PMID 39521433, PMID 39694978, PMID 39759832, PMID 39983053, PMID 40466026, PMID 40617171, PMID 41023484, PMID 41130408, PMID 41166674, PMID 41780641, PMID 41963505, PMID 41986720, PMID 41996652, PMID 42223087, PMID 42361644
2019 (3), 2023 (3), 2018 (2), U10CA180886 (2), U10CA180888 (2), 2017 (1)